Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EBMT 2020 | Duvelisib in CAR T-cell therapy for CLL

Edmund Waller • 1 Sep 2020
EBMT 2020
Chronic Lymphocytic Leukemia Leukemia Duvelisib

Edmund Waller, MD, PhD, FACP, Division of Hematology/Oncology, Emory Clinic, Atlanta, GA, outlines the use and activity of duvelisib in CAR T-cell therapy for patients with chronic lymphocytic leukemia (CLL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Edmund Waller

Managing GvHD in patients undergoing SCT
1:12
Managing GvHD in patients undergoing SCT
Edmund Waller • 8 Sep 2023
Optimizing conditioning regimens in patients with AML undergoing alloSCT
1:46
Optimizing conditioning regimens in patients with AML undergoing alloSCT
Edmund Waller • 8 Sep 2023
Improving transplantation outcomes in patients with active AML: current approaches & future outlooks
2:09
Improving transplantation outcomes in patients with active AML: current approaches & future outlooks
Edmund Waller • 8 Sep 2023
PORTIA: tisagenlecleucel and pembrolizumab in R/R DLBCL
5:01
PORTIA: tisagenlecleucel and pembrolizumab in R/R DLBCL
Edmund Waller • 23 Aug 2020

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Edmund Waller • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Edmund Waller • 6 Dec 2025
Beat AML abstracts at ASH 2025: ficlatuzumab sub-study, PRISM score, and the impact of co-mutations
3:16
Beat AML abstracts at ASH 2025: ficlatuzumab sub-study, PRISM score, and the impact of co-mutations
Edmund Waller • 6 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Edmund Waller • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals